P. Kosinski

发表

Resveratrol inhibits firefly luciferase.

Adel Bakhtiarova, D. Kemp, B. Hubbard, 2006, Biochemical and biophysical research communications.

Heat shock protein 90 (HSP90) inhibitors activate the heat shock factor 1 (HSF1) stress response pathway and improve glucose regulation in diabetic mice.

T. Hughes, J. Gromada, D. Kemp, 2013, Biochemical and biophysical research communications.

Contribution of human bone marrow stem cells to individual skeletal myotubes followed by myogenic gene activation.

D. Kemp, Jee-Hyung Lee, Penelope A Kosinski, 2005, Experimental cell research.

Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells.

B. Bowen, C. Cioffi, P. Kosinski, 2003, Biochemical and biophysical research communications.

AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes

C. Kung, J. Hixon, L. Dang, 2020, Haematologica.

Nucleolin Is a Second Component of the CD154 mRNA Stability Complex That Regulates mRNA Turnover in Activated T Cells1

Karnail Singh, P. Kosinski, L. Covey, 2004, The Journal of Immunology.

CellsRegulates mRNA Turnover in Activated T CD154 mRNA Stability Complex That Nucleolin Is a Second Component of the

Karnail Singh, P. Kosinski, L. Covey, 2004 .

A Complex Containing Polypyrimidine Tract-Binding Protein Is Involved in Regulating the Stability of CD40 Ligand (CD154) mRNA1

Karnail Singh, P. Kosinski, L. Covey, 2003, The Journal of Immunology.

Regulating the Stability of CD 40 Ligand Tract-Binding Protein Is Involved in A Complex Containing Polypyrimidine

Karnail Singh, P. Kosinski, L. Covey, 2002 .

Identification of a Complex that Binds to the CD154 3′ Untranslated Region: Implications for a Role in Message Stability During T Cell Activation1

M. Kiledjian, Zuo-ren Wang, B. Barnhart, 2000, The Journal of Immunology.

Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency.

A. Schambach, C. Kung, Shengfang Jin, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study

K. Uhlig, E. Vichinsky, A. Lal, 2022, The Lancet.

AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.

Yaguang Si, C. Kung, J. Hixon, 2017, Blood.

P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

E. Vichinsky, A. Lal, H. Al‐Samkari, 2022, HemaSphere.

P1547: ACTIVATE-KIDS: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED

V. Beynon, P. Tyler, P. Kosinski, 2022, HemaSphere.

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY

V. Beynon, H. Al‐Samkari, P. Kosinski, 2022, HemaSphere.

P1546: ACTIVATE-KIDST: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED

V. Beynon, P. Tyler, P. Kosinski, 2022, HemaSphere.

S273: EVIDENCE OF NONINFERIORITY OF MITAPIVAT VERSUS SPLENECTOMY IN MURINE HEREDITARY SPHEROCYTOSIS

A. Iolascon, L. De Franceschi, C. Brugnara, 2022, HemaSphere.

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY

V. Viprakasit, F. Galactéros, V. Beynon, 2021, HemaSphere.

Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency

V. Beynon, H. Al‐Samkari, P. Kosinski, 2021, Blood.

Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells

F. Prósper, C. Kung, Shengfang Jin, 2015, Stem cell reports.

Identification of novel pathway regulation during myogenic differentiation.

J. Szustakowski, N. Nirmala, D. Kemp, 2006, Genomics.

Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

J. Nichols, E. Henry, W. Eaton, 2020, Blood.

Dynamic resolution of functionally related gene sets in response to acute heat stress

J. Szustakowski, D. Kemp, S. Elliman, 2007, BMC Molecular Biology.

The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency

D. Morton, C. Kung, Y. Ravindranath, 2020, British journal of haematology.

A fit-for-purpose LC-MS/MS method for the simultaneous quantitation of ATP and 2,3-DPG in human K2EDTA whole blood.

C. Kung, Hua Yang, L. Dang, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers

C. Kung, Hua Yang, M. Goldwasser, 2018, Clinical pharmacology in drug development.

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for therapy by mitapivat.

C. Kung, L. Dang, V. Chubukov, 2021, Blood.

Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study

D. Morton, C. Kung, J. Hixon, 2016 .

The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.

C. Kung, L. Dang, T. Ganz, 2021, The Journal of clinical investigation.

Metabolic Profiling Using Stable Isotope Tracing Reveals Distinct Patterns of Glucose Utilization by Physiologically Activated CD8+ T Cells.

Takla Griss, E. Ma, B. Faubert, 2019, Immunity.

A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease.

W. Eaton, C. Kung, L. Dang, 2022, Blood.

Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients

C. Kung, L. Dang, J. Jans, 2021, Blood.

The Pyruvate Kinase Activator Mitapivat Ameliorates Anemia and Prevents Iron Overload in a Mouse Model of Hereditary Spherocytosis

C. Kung, L. Dang, C. Brugnara, 2020 .

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

A. Lal, H. Al‐Samkari, D. Layton, 2021, HemaSphere.

Mitapivat Improves Transfusion Burden and Reduces Iron Overload in Thalassemic Mice

L. Dang, L. De Franceschi, C. Brugnara, 2021, Blood.

Uncovering mechanisms of transcriptional regulations by systematic mining of cis regulatory elements with gene expression profiles

Qicheng Ma, Gung-Wei Chirn, Joseph D. Szustakowski, 2008, BioData Mining.

Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.

W. Eaton, C. Kung, L. Dang, 2022, Blood cells, molecules & diseases.

Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study

W. Eaton, C. Kung, L. Dang, 2021, Blood.